This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Graphite Bio 将来の成長

Future 基準チェック /06

Graphite Bio は収益が増加すると予測されています。EPS は、年間増加すると予測されています73.8%。

主要情報

36.4%

収益成長率

73.8%

EPS成長率

Biotechs 収益成長	27.3%
収益成長率	n/a
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	15 Nov 2023

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

NasdaqGM:GRPH - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	N/A	-23	N/A	N/A	1
12/31/2025	N/A	-23	N/A	N/A	1
12/31/2024	N/A	-23	N/A	N/A	1
12/31/2023	N/A	-125	-101	-90	N/A
9/30/2023	N/A	-126	-78	-67	N/A
6/30/2023	N/A	-129	-87	-79	N/A
3/31/2023	N/A	-99	-92	-88	N/A
12/31/2022	N/A	-101	-95	-88	N/A
9/30/2022	N/A	-95	-88	-81	N/A
6/30/2022	N/A	-85	-84	-74	N/A
3/31/2022	N/A	-77	-75	-66	N/A
12/31/2021	N/A	-71	-59	-53	N/A
9/30/2021	N/A	-115	-48	-43	N/A
6/30/2021	N/A	-104	-32	-30	N/A
3/31/2021	N/A	-88	-19	-17	N/A
12/31/2020	N/A	-68	-10	-9	N/A

アナリストによる今後の成長予測

収入対貯蓄率: GRPH今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: GRPH今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: GRPH今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: GRPHの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。

高い収益成長: GRPH来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: GRPHの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

This company is no longer active

Graphite Bio 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 23% to US$2.83

Price target decreased to US$10.86

Recent updates

Graphite Bio, Inc.(NasdaqGM:GRPH) dropped from NASDAQ Composite Index

New major risk - Share price stability

Graphite Bio, Inc. Declares Special Dividend, Payable on March 21, 2024

Graphite Bio, Inc. Declares Special Dividend, Payable on March 21, 2024

LENZ Therapeutics, Inc. entered into a definitive merger agreement to acquire Graphite Bio, Inc. (NasdaqGM:GRPH) for approximately $230 million in a reverse merger transaction.

Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

Graphite Bio, Inc. Announces Executive Changes

Graphite Bio, Inc. Appoints Kimberlee C. Drapkin as Independent Director

Graphite Bio, Inc Announces Departure of Alethia Young as Chief Financial Officer

Graphite Bio, Inc., Annual General Meeting, Jul 19, 2023

We're Hopeful That Graphite Bio (NASDAQ:GRPH) Will Use Its Cash Wisely

Price target decreased by 23% to US$2.83

Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?

Graphite Bio, Inc. Announces Voluntary Pause of Phase 1/2 Cedar Study of Nulabeglogene Autogedtemcel (Nula-Cel) for Sickle Cell Disease

Price target decreased to US$10.86

Graphite Bio, Inc. Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting

High number of new and inexperienced directors

Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation

Graphite Bio, Inc. Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease

Graphite Bio doses first patient with GPH101 for sickle cell disease

Graphite Bio, Inc.(NasdaqGM:GRPH) dropped from Russell 2500 Value Index

Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?

Graphite Bio: Selling For Much Less Than Net Cash

Graphite Bio, Inc. Presents Preclinical Gene Replacement Data for GPH102 for Beta-Thalassemia at the ASGCT 25 Annual Meeting

Graphite Bio, Inc., Annual General Meeting, Jun 21, 2022

High number of new and inexperienced directors

Graphite Bio, Inc. Announces Management Changes

Graphite Bio, Inc. Announces Executive Changes

High number of new and inexperienced directors

Graphite Bio, Inc. Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition

Graphite Bio: An Important Stock To Track In The Gene Editing Space

Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans

Graphite Bio: Assessing Prospects Amid Doubts Raised On Safety Of Crispr

Graphite Bio, Inc. has completed an IPO in the amount of $238 million.

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘